Eric TopolThe 1st results for the @BharatBiotech nasal vaccine (BBV154, approved in India) randomized trial vs shots now posted, superior antibody and cellular immune response (vs ancestral and Omicron); 4-fold less side effects https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4342771
PamW
Horst Storkebaum@erictopol
Thanks Eric!
Promising news!
Would you please also point us to the final version of that study once it will be published and of course further publications of the same project. I assume they have continued to monitor how the immunity parameters developed at later points in time after the vaccination.